Long-term survival after TAVI in low-flow, low-gradient aortic valve stenosis.

IF 7.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Francesco Cardaioli, Luca Nai Fovino, Tommaso Fabris, Giulia Masiero, Federico Arturi, Andrea Panza, Andrea Bertolini, Giulio Rodinò, Saverio Continisio, Massimo Napodano, Giulia Lorenzoni, Dario Gregori, Chiara Fraccaro, Giuseppe Tarantini
{"title":"Long-term survival after TAVI in low-flow, low-gradient aortic valve stenosis.","authors":"Francesco Cardaioli, Luca Nai Fovino, Tommaso Fabris, Giulia Masiero, Federico Arturi, Andrea Panza, Andrea Bertolini, Giulio Rodinò, Saverio Continisio, Massimo Napodano, Giulia Lorenzoni, Dario Gregori, Chiara Fraccaro, Giuseppe Tarantini","doi":"10.4244/EIJ-D-24-00442","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In patients undergoing transcatheter aortic valve implantation (TAVI), the presence of a low-flow, low-gradient (LFLG) status has been associated with higher mortality at short-term follow-up.</p><p><strong>Aims: </strong>We aimed to evaluate long-term survival after TAVI in patients with classical (cLFLG) and paradoxical LFLG (pLFLG) aortic stenosis (AS) compared to high-gradient (HG)-AS.</p><p><strong>Methods: </strong>Patients undergoing TAVI at our centre with a hypothetical minimum 5-year follow-up were divided into 3 groups: (1) HG-AS (mean gradient [MG] >40 mmHg), (2) cLFLG-AS (MG <40 mmHg, ejection fraction [EF] <50%), and (3) pLFLG-AS (MG <40 mmHg, EF ≥50%). The primary endpoint of the study was all-cause mortality. Propensity score-weighted survival analysis was performed to adjust for possible baseline confounders.</p><p><strong>Results: </strong>A total of 574 subjects were included (73% HG-AS, 15% pLFLG-AS, 11% cLFLG-AS). The median survival time was 4.8 years, with a maximum of 12.3 years. Patients with cLFLG-AS presented the highest baseline cardiovascular risk. At unadjusted survival analysis, patients with cLFLG-AS showed the worst long-term prognosis, with a rapid decrease in survival within the first year, while pLFLG- and HG-AS patients presented similar survival rates (p=0.023). At weighted long-term analysis, cLFLG- and HG-AS had similar survival rates. Baseline EF was not related to long-term mortality, while patients with a post-TAVI left ventricular ejection fraction (LVEF) improvement >10% lived significantly longer (p=0.02).</p><p><strong>Conclusions: </strong>Classical LFLG-AS patients had lower long-term survival rates as compared to pLFLG-AS and HG-AS patients. However, after adjustment for possible baseline confounders, a low-flow status per se did not have an impact on long-term mortality after TAVI. Post-TAVI LVEF recovery was associated with improved long-term outcome.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 22","pages":"1380-1389"},"PeriodicalIF":7.6000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556328/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurointervention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4244/EIJ-D-24-00442","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In patients undergoing transcatheter aortic valve implantation (TAVI), the presence of a low-flow, low-gradient (LFLG) status has been associated with higher mortality at short-term follow-up.

Aims: We aimed to evaluate long-term survival after TAVI in patients with classical (cLFLG) and paradoxical LFLG (pLFLG) aortic stenosis (AS) compared to high-gradient (HG)-AS.

Methods: Patients undergoing TAVI at our centre with a hypothetical minimum 5-year follow-up were divided into 3 groups: (1) HG-AS (mean gradient [MG] >40 mmHg), (2) cLFLG-AS (MG <40 mmHg, ejection fraction [EF] <50%), and (3) pLFLG-AS (MG <40 mmHg, EF ≥50%). The primary endpoint of the study was all-cause mortality. Propensity score-weighted survival analysis was performed to adjust for possible baseline confounders.

Results: A total of 574 subjects were included (73% HG-AS, 15% pLFLG-AS, 11% cLFLG-AS). The median survival time was 4.8 years, with a maximum of 12.3 years. Patients with cLFLG-AS presented the highest baseline cardiovascular risk. At unadjusted survival analysis, patients with cLFLG-AS showed the worst long-term prognosis, with a rapid decrease in survival within the first year, while pLFLG- and HG-AS patients presented similar survival rates (p=0.023). At weighted long-term analysis, cLFLG- and HG-AS had similar survival rates. Baseline EF was not related to long-term mortality, while patients with a post-TAVI left ventricular ejection fraction (LVEF) improvement >10% lived significantly longer (p=0.02).

Conclusions: Classical LFLG-AS patients had lower long-term survival rates as compared to pLFLG-AS and HG-AS patients. However, after adjustment for possible baseline confounders, a low-flow status per se did not have an impact on long-term mortality after TAVI. Post-TAVI LVEF recovery was associated with improved long-term outcome.

低流量、低梯度主动脉瓣狭窄的 TAVI 术后长期存活率。
背景:目的:与高梯度(HG)主动脉瓣狭窄(AS)相比,我们旨在评估经典(cLFLG)和矛盾LFLG(pLFLG)主动脉瓣狭窄(AS)患者TAVI术后的长期存活率:在本中心接受TAVI手术的患者被分为3组:(1) HG-AS(平均梯度[MG]>40 mmHg);(2) cLFLG-AS(平均梯度[MG]>40 mmHg);(3) pLFLG-AS(平均梯度[MG]>40 mmHg):共纳入 574 名受试者(73% HG-AS、15% pLFLG-AS、11% cLFLG-AS)。中位生存时间为 4.8 年,最长为 12.3 年。cLFLG-AS患者的基线心血管风险最高。在未经调整的生存分析中,cLFLG-AS 患者的长期预后最差,第一年内生存率迅速下降,而 pLFLG- 和 HG-AS 患者的生存率相似(p=0.023)。在加权长期分析中,cLFLG-和HG-AS的存活率相似。基线EF与长期死亡率无关,而TAVI术后左室射血分数(LVEF)改善>10%的患者存活时间明显更长(P=0.02):结论:与pLFLG-AS和HG-AS患者相比,经典LFLG-AS患者的长期生存率较低。然而,在对可能的基线混杂因素进行调整后,低血流状态本身对TAVI术后的长期死亡率没有影响。TAVI术后LVEF的恢复与长期预后的改善有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Eurointervention
Eurointervention CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
10.30
自引率
4.80%
发文量
380
审稿时长
3-8 weeks
期刊介绍: EuroIntervention Journal is an international, English language, peer-reviewed journal whose aim is to create a community of high quality research and education in the field of percutaneous and surgical cardiovascular interventions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信